Literature DB >> 16407690

Pharmacotherapy review: calcium channel blockers.

Domenic A Sica1.   

Abstract

As a drug class, calcium channel blockers encompass a heterogeneous group of compounds with distinctive structures and pharmacologic characteristics. These agents are widely used in the treatment of hypertension, chronic coronary ischemia, and/or supraventricular arrhythmias. Much of the early debate alluding to increased cardiovascular risk associated with calcium channel blocker use has been silenced by an array of outcomes trials that show these drugs to be both safe and effective in reducing hard cardiovascular end points. The most common side effects associated with calcium channel blockers are vasodilatory in nature and include a non-volume-dependent form of peripheral edema, flushing, and headache. Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407690      PMCID: PMC8109625          DOI: 10.1111/j.1524-6175.2005.04140.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  4 in total

1.  Cardiovascular protection and blood pressure reduction: a meta-analysis.

Authors:  J A Staessen; J G Wang; L Thijs
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

2.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

Authors:  Fiona Turnbull; Bruce Neal; Charles Algert; John Chalmers; Neil Chapman; Jeff Cutler; Mark Woodward; Stephen MacMahon
Journal:  Arch Intern Med       Date:  2005-06-27

3.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

4.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

  4 in total
  16 in total

1.  Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.

Authors:  Diogo M O Marçal; Elen Rizzi; Alisson Martins-Oliveira; Carla S Ceron; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-31       Impact factor: 3.000

2.  Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.

Authors:  Robert Lins; Yves Haerden; Caroline de Vries
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-03

Review 3.  Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2010       Impact factor: 9.546

4.  Epidemiology and management of antiretroviral-associated cardiovascular disease.

Authors:  Daniel B Chastain; Harold Henderson; Kayla R Stover
Journal:  Open AIDS J       Date:  2015-03-31

Review 5.  Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension.

Authors:  Anna Bitner; Paweł Zalewski; Jacek J Klawe; Julia L Newton
Journal:  Drugs Real World Outcomes       Date:  2015-03

Review 6.  Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs.

Authors:  Mayank Sharma; Rajesh Sharma; Dinesh Kumar Jain
Journal:  Scientifica (Cairo)       Date:  2016-04-30

7.  Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial.

Authors:  Priyadarshani Galappatthy; Yasindu C Waniganayake; Mohomad I M Sabeer; Thusitha J Wijethunga; Gamini K S Galappatthy; Ruvan Ai Ekanayaka
Journal:  BMC Cardiovasc Disord       Date:  2016-09-01       Impact factor: 2.298

8.  The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.

Authors:  J Schrader; A Salvetti; C Calvo; E Akpinar; L Keeling; M Weisskopf; P Brunel
Journal:  Int J Clin Pract       Date:  2009-02       Impact factor: 2.503

9.  Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis.

Authors:  S Ranjbar; O Firuzi; N Edraki; O Shahraki; L Saso; M Khoshneviszadeh; R Miri
Journal:  Medchemcomm       Date:  2017-08-23       Impact factor: 3.597

Review 10.  Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.